• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

后记:口服蛋氨酸酶——癌症的答案与青春之泉?

Afterword: Oral Methioninase-Answer to Cancer and Fountain of Youth?

作者信息

Hoffman Robert M, Han Qinghong, Kawaguchi Kei, Li Shukuan, Tan Yuying

机构信息

AntiCancer, Inc., San Diego, CA, USA.

Department of Surgery, University of California, San Diego, CA, USA.

出版信息

Methods Mol Biol. 2019;1866:311-322. doi: 10.1007/978-1-4939-8796-2_24.

DOI:10.1007/978-1-4939-8796-2_24
PMID:30725426
Abstract

The elevated methionine (MET) requirement of cancer cells is termed MET dependence and is possibly the only known general metabolic defect in cancer. Targeting MET by recombinant methioninase (rMETase) can arrest the growth of cancer cells in vitro and in vivo due to their elevated requirement for MET. rMETase can also potentiate chemotherapy drugs active in S phase due to the selective arrest of cancer cells in S/G phase during MET restriction (MR). We previously reported that rMETase, administrated by intraperitoneal injection (ip-rMETase), could inhibit tumor growth in mouse models of cancer including patient-derived orthotopic xenograft (PDOX) mouse models. We subsequently compared ip-rMETase and oral rMETase (o-rMETase) on a melanoma PDOX mouse model. o-rMETase was significantly more effective than ip-rMETase to inhibit tumor growth without overt toxicity. The combination of o-rMETase+ip-rMETase was significantly more effective than either monotherapy and completely arrested tumor growth. Thus, o-rMETase is effective as an anticancer agent with the potential of clinical development for chronic cancer therapy as well as for cancer prevention. o-rMETase may also have potential as an antiaging agent for healthy people, since MR has been shown to extend the life span of a variety of different organisms.

摘要

癌细胞对蛋氨酸(MET)的需求增加被称为MET依赖性,这可能是癌症中唯一已知的普遍代谢缺陷。通过重组蛋氨酸酶(rMETase)靶向MET可以在体外和体内抑制癌细胞的生长,因为它们对MET的需求增加。由于在MET限制(MR)期间癌细胞在S/G期的选择性停滞,rMETase还可以增强在S期具有活性的化疗药物的作用。我们之前报道过,通过腹腔注射给药的rMETase(ip-rMETase)可以抑制癌症小鼠模型中的肿瘤生长,包括患者来源的原位异种移植(PDOX)小鼠模型。我们随后在黑色素瘤PDOX小鼠模型上比较了ip-rMETase和口服rMETase(o-rMETase)。o-rMETase在抑制肿瘤生长方面比ip-rMETase显著更有效,且无明显毒性。o-rMETase + ip-rMETase联合治疗比单一疗法显著更有效,并完全抑制了肿瘤生长。因此,o-rMETase作为一种抗癌剂是有效的,具有用于慢性癌症治疗以及癌症预防的临床开发潜力。o-rMETase对于健康人也可能具有作为抗衰老剂的潜力,因为已经证明MR可以延长多种不同生物体的寿命。

相似文献

1
Afterword: Oral Methioninase-Answer to Cancer and Fountain of Youth?后记:口服蛋氨酸酶——癌症的答案与青春之泉?
Methods Mol Biol. 2019;1866:311-322. doi: 10.1007/978-1-4939-8796-2_24.
2
Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.用口服重组蛋氨酸酶(o-rMETase)靶向蛋氨酸可阻断 BRAF-V600E 突变黑色素瘤的患者来源的原位异种移植(PDOX)模型:对慢性临床癌症治疗和预防的影响。
Cell Cycle. 2018;17(3):356-361. doi: 10.1080/15384101.2017.1405195. Epub 2018 Mar 19.
3
Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review.重组甲硫氨酸酶(rMETase)在难治性癌症患者来源的原位异种移植(PDOX)小鼠模型中的疗效:综述。
Cells. 2019 May 2;8(5):410. doi: 10.3390/cells8050410.
4
High Efficacy of Recombinant Methioninase on Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer.重组蛋氨酸酶对癌症患者原位移植瘤(PDOX)小鼠模型的高效性
Methods Mol Biol. 2019;1866:149-161. doi: 10.1007/978-1-4939-8796-2_12.
5
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.重组蛋氨酸酶在患者来源的原位异种移植(PDOX)裸鼠模型中有效靶向尤因肉瘤。
Oncotarget. 2017 May 30;8(22):35630-35638. doi: 10.18632/oncotarget.15823.
6
Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.用重组蛋氨酸酶(rMETase)靶向改变的癌症蛋氨酸代谢克服部分吉西他滨耐药性,并使胰腺癌患者来源的原位异种移植(PDOX)裸鼠模型消退。
Cell Cycle. 2018;17(7):868-873. doi: 10.1080/15384101.2018.1445907. Epub 2018 May 21.
7
Methioninase Cell-Cycle Trap Cancer Chemotherapy.甲硫氨酸酶细胞周期陷阱癌症化疗
Methods Mol Biol. 2019;1866:133-148. doi: 10.1007/978-1-4939-8796-2_11.
8
Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model.口服重组蛋氨酸酶联合咖啡因和阿霉素诱导人源化小鼠模型中阿霉素耐药性滑膜肉瘤消退
Anticancer Res. 2018 Oct;38(10):5639-5644. doi: 10.21873/anticanres.12899.
9
Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.肿瘤靶向鼠伤寒沙门氏菌 A1-R 与口服重组蛋氨酸酶联合治疗使 BRAF-V600E 阴性黑色素瘤消退。
Biochem Biophys Res Commun. 2018 Sep 18;503(4):3086-3092. doi: 10.1016/j.bbrc.2018.08.097. Epub 2018 Aug 27.
10
Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.口服重组蛋氨酸酶联合紫杉醇在患者来源的原位异种移植(PDOX)裸鼠模型中阻止难治性卵巢透明细胞癌的生长。
Cancer Chemother Pharmacol. 2021 Jul;88(1):61-67. doi: 10.1007/s00280-021-04261-x. Epub 2021 Mar 25.

引用本文的文献

1
Methionine Dependency and Restriction in Cancer: Exploring the Pathogenic Function and Therapeutic Potential.癌症中的甲硫氨酸依赖性与限制:探索致病功能和治疗潜力
Pharmaceuticals (Basel). 2025 Apr 28;18(5):640. doi: 10.3390/ph18050640.